- Home
- CRIS vs CGTX Comparison
CRIS vs CGTX Comparison
Compare CRIS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRIS
- CGTX
- Stock Information
- Founded
- CRIS 2000
- CGTX 2007
- Country
- CRIS United States
- CGTX United States
- Employees
- CRIS N/A
- CGTX N/A
- Industry
- CRIS Biotechnology: Biological Products (No Diagnostic Substances)
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- CRIS Health Care
- CGTX Health Care
- Exchange
- CRIS Nasdaq
- CGTX Nasdaq
- Market Cap
- CRIS 21.3M
- CGTX 20.5M
- IPO Year
- CRIS 2000
- CGTX 2021
- Fundamental
- Price
- CRIS $2.32
- CGTX $0.30
- Analyst Decision
- CRIS Strong Buy
- CGTX Strong Buy
- Analyst Count
- CRIS 2
- CGTX 5
- Target Price
- CRIS $16.50
- CGTX $5.63
- AVG Volume (30 Days)
- CRIS 71.8K
- CGTX 1.9M
- Earning Date
- CRIS 07-31-2025
- CGTX 08-07-2025
- Dividend Yield
- CRIS N/A
- CGTX N/A
- EPS Growth
- CRIS N/A
- CGTX N/A
- EPS
- CRIS N/A
- CGTX N/A
- Revenue
- CRIS $11,202,000.00
- CGTX N/A
- Revenue This Year
- CRIS N/A
- CGTX N/A
- Revenue Next Year
- CRIS $10.67
- CGTX N/A
- P/E Ratio
- CRIS N/A
- CGTX N/A
- Revenue Growth
- CRIS 14.17
- CGTX N/A
- 52 Week Low
- CRIS $1.02
- CGTX $0.22
- 52 Week High
- CRIS $8.29
- CGTX $2.54
- Technical
- Relative Strength Index (RSI)
- CRIS 52.52
- CGTX 48.87
- Support Level
- CRIS $2.11
- CGTX $0.25
- Resistance Level
- CRIS $2.26
- CGTX $0.33
- Average True Range (ATR)
- CRIS 0.21
- CGTX 0.03
- MACD
- CRIS -0.04
- CGTX 0.00
- Stochastic Oscillator
- CRIS 21.36
- CGTX 58.69
About CRIS Curis Inc.
Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.